Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · IEX Real-Time Price · USD
10.41
-0.65 (-5.88%)
May 16, 2022 4:00 PM EDT - Market closed

Income Statement (Annual)

Millions USD. Fiscal year is Jan - Dec.
Year202120202019
Revenue
3.6400
Gross Profit
3.6400
Selling, General & Admin
10.331.80.77
Research & Development
26.243.043
Operating Expenses
36.574.843.77
Operating Income
-32.93-4.84-3.77
Interest Expense / Income
00.210.23
Other Expense / Income
-0.261.740
Pretax Income
-32.67-6.78-4
Net Income
-32.67-6.78-4
Net Income Common
-32.67-6.78-4
Shares Outstanding (Basic)
2411
Shares Outstanding (Diluted)
2411
Shares Change
2471.20%36.71%-
EPS (Basic)
-1.39-7.41-5.98
EPS (Diluted)
-1.39-7.41-5.98
Free Cash Flow Per Share
-0.78-4.77-5.72
Gross Margin
100.00%--
Operating Margin
-905.39%--
Profit Margin
-898.32%--
Free Cash Flow Margin
-507.51%--
EBITDA
-32.56-6.57-3.77
EBITDA Margin
-895.22%--
EBIT
-32.67-6.58-3.77
EBIT Margin
-898.32%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).